Author Archives: Bruno Quinney

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

DDW Highlights: 24 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More

#Podcasts

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

This week in Drug Discovery (16 – 20 February) 

News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW.  This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy.  The top stories:    Psychedelic drug could help treat depression … Read More

#News

#Chronic kidney disease (CKD) #Clinical trial #Japan

Asahi Kasei Pharma advances refractory disease drug to trial 

Asahi Kasei Pharma has advanced its treatment for refractory diseases to Phase I clinical trial.  AK1960, a novel Endothelin A (ETA) receptor antagonist, has been developed in collaboration with drug discovery company Alchemedicine, which entered a license agreement with Asahi Kasei Pharma in 2022.  In preclinical… Read More

#News

Diabetic eye disease
#Axol Bioscience #Ophthalmology #Stem cells

Axol to progress eye disease treatments with new acquisition 

Stem cell technologies company Axol Bioscience has acquired the ophthalmology business of Newcells Biotech.  The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services to biopharma, biotechnology and CRO customers across Europe and… Read More

#News

Female scientist in the lab
#Drug design #Nuclera #Proteins

Nuclera and leadXpro to design drugs for membrane proteins 

Biotechnology company Nuclera has partnered with leadXpro on structure-based drug design for complex membrane proteins.  The collaboration will bring together Nuclera’s eProtein Discovery system with leadXpro’s AI/ML-driven construct design and membrane protein expertise to advance structural studies and therapeutic development.  Membrane proteins remain some of the most valuable yet difficult to obtain drug targets. The proteins are notoriously challenging… Read More

#News

Ovarian cancer cells
#Clinical trial #Oncology #Ovarian cancer

Ovarian cancer treatment could prevent peritoneal recurrence 

A new treatment for ovarian cancer could prevent peritoneal recurrence, data suggests.  Biotech company Oncoinvent is set to present results from the Phase I study of Radspherin after cytoreductive surgery in patients with platinums ensitivesensitive epithelial ovarian cancer. According to data released in advance, nine of 10 patients treated on the highest dose remained free… Read More

#Cancer Research #News

Node structures in the central nervous system
#Clinical trial #Newron Pharmaceuticals #Schizophrenia

Newron raises €38m to advance schizophrenia treatment 

Biopharmaceuticals company Newron Pharmaceuticals has secured €38 million to advance novel therapies for patients with diseases of the central and peripheral nervous system.  The capital, raised through newly issued shares, is set to accelerate the company’s ENIGMA-TRS Phase III programme, evaluating the safety and efficacy of evenamide as an add-on therapy… Read More

#News

#Cancer Research Horizons #Genome sequencing #RNA sequencing #UK

Oesophageal cancer dataset made available for commercial use 

Cancer Research Horizons has made one the largest oesophageal cancer datasets available for commercial licensing.  Developed by a team led by Professor Rebecca Fitzgerald at the University of Cambridge, the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) dataset represents one of the world’s largest and most comprehensive collections… Read More

#Cancer Research #News

#Cyber security #Lab automation #United States

Preparing for cyber-risks in the lab

Dr Marc Porr, Founder and CEO of TechkIT, examines the cyber-security risks that have reached the automated lab.  About a year ago Mark Auty from Unilever wrote about new cyber security challenges arising… Read More

#Exclusive Content

Weight loss concept
#European Commission #Novo Nordisk #Obesity

Higher dosage of Wegovy more effective for weight loss 

The European Commission (EC) has approved a higher dosage of obesity drug Wegovy which has proved it can help adults lose weight more effectively.  Final approval has been granted to a new 7.2mg once-weekly maintenance dose of Wegovy (semaglutide injection), giving doctors another treatment option alongside the previous 2.4mg… Read More

#News #Regulatory

#AI #Drug discovery #Women's health

Partnership to develop treatments for gynaecological diseases 

Tejin Pharma has partnered with pharmaceutical company Aska Pharmaceutical to develop treatments for gynaecological diseases.  As per the agreement, the companies will collaborate to accelerate the early-stage drug discovery process aimed at identifying innovative therapeutic candidates.   The companies intend to develop novel small-molecule drug candidates, a process which… Read More

#News

Psychiatrist with patient
#Depression #Psychedelics #Treatment-resistant depression

Psychedelic drug could help treat depression 

The psychedelic drug dimethyltryptamine (DMT) could help treat depression when combined with psychotherapy, The Guardian has reported.  According to preliminary results reported in Nature Medicine, a trial involving 34 patients found that psychotherapy combined with DMT caused a reduction in depressive symptoms, even after the… Read More

#News

Doctor points at child's brain scan
#Biosimilars #Cerebral Palsy #Thermo Fisher Scientific #Treehill Partners

New company to advance cerebral palsy therapy 

A new regenerative medicine company is set to develop a novel cell and gene therapy targeting paediatric cerebral palsy (CP).  Kidswell USA has been formed by a partnership between biosimilars and cell therapies company Kidswell Bio Corporation and corporate development advisor Treehill Partners.  In the new company, Kidswell and Treehill aim to advance their… Read More

#News